Factors affecting nonrelapse mortality
. | No. . | Nonrelapse deaths, no. (%) . | HR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Age | |||||
| 50 y or younger | 48 | 19 (40) | — | — | — |
| Older than 50 y | 15 | 7 (47) | 1.2 | 0.5-2.9 | .7 |
| Sex | |||||
| Female | 30 | 14 (47) | — | — | — |
| Male | 33 | 12 (36) | 0.7 | 0.3-1.4 | .3 |
| Donor type | |||||
| Matched sibling | 38 | 15 (39) | 0.8 | 0.4-1.8 | .6 |
| Other | 21 | 11 (52) | — | — | — |
| Acute GVHD | |||||
| Grades 2-4 | 33 | 15 (45) | 1.9 | 0.8-4.6 | .1 |
| All other | 30 | 8 (33) | — | — | — |
| No. prior treatments* | |||||
| 2 | 40 | 12 (30) | — | — | — |
| 3 | 23 | 14 (61) | 2.8 | 1.25-6.1 | .01 |
| Steroids at ECP | |||||
| Yes | 11 | 4 (36) | — | — | — |
| No | 52 | 22 (42) | 1.5 | 0.5-4.3 | .5 |
| Chronic GVHD | |||||
| De novo | 17 | 6 (35) | — | — | — |
| Progressive | 16 | 8 (50) | 3 | 1.0-8.9 | .04 |
| Relapsing | 30 | 12 (40) | 1.6 | 0.5-3.8 | .5 |
| Scleroderma† | |||||
| Yes | 21 | 6 (29) | 0.4 | 0.1-0.99 | .05 |
| No | 29 | 14 (48) | — | — | — |
| Response to tacrolimus/MP | |||||
| CR/PR | 7 | 4 (57) | 1.9 | 0.6-5.9 | .2 |
| All other | 56 | 22 (39) | — | — | — |
| Response to ECP‡ | |||||
| CR/PR | 37 | 9 (24) | 0.2 | 0.1-0.5 | < .001 |
| All others | 25 | 17 (65) | — | — | — |
| Platelets at ECP | |||||
| Fewer than 100 000/mm3§ | 24 | 16 (67) | 7.25 | 3.1-16.9 | < .001 |
| 100 000/mm3 or more | 38 | 10 (26) | — | — | — |
| Unknown | 1 | 2 (—) | — | — | — |
| LDH | |||||
| 1000 IU/L or less | 41 | 14 (35) | — | — | — |
| More than 1000 IU/L | 20 | 12 (60) | 3.1 | 1.4-6.9 | .005 |
| Unknown | 2 | — (—) | — | — | — |
. | No. . | Nonrelapse deaths, no. (%) . | HR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Age | |||||
| 50 y or younger | 48 | 19 (40) | — | — | — |
| Older than 50 y | 15 | 7 (47) | 1.2 | 0.5-2.9 | .7 |
| Sex | |||||
| Female | 30 | 14 (47) | — | — | — |
| Male | 33 | 12 (36) | 0.7 | 0.3-1.4 | .3 |
| Donor type | |||||
| Matched sibling | 38 | 15 (39) | 0.8 | 0.4-1.8 | .6 |
| Other | 21 | 11 (52) | — | — | — |
| Acute GVHD | |||||
| Grades 2-4 | 33 | 15 (45) | 1.9 | 0.8-4.6 | .1 |
| All other | 30 | 8 (33) | — | — | — |
| No. prior treatments* | |||||
| 2 | 40 | 12 (30) | — | — | — |
| 3 | 23 | 14 (61) | 2.8 | 1.25-6.1 | .01 |
| Steroids at ECP | |||||
| Yes | 11 | 4 (36) | — | — | — |
| No | 52 | 22 (42) | 1.5 | 0.5-4.3 | .5 |
| Chronic GVHD | |||||
| De novo | 17 | 6 (35) | — | — | — |
| Progressive | 16 | 8 (50) | 3 | 1.0-8.9 | .04 |
| Relapsing | 30 | 12 (40) | 1.6 | 0.5-3.8 | .5 |
| Scleroderma† | |||||
| Yes | 21 | 6 (29) | 0.4 | 0.1-0.99 | .05 |
| No | 29 | 14 (48) | — | — | — |
| Response to tacrolimus/MP | |||||
| CR/PR | 7 | 4 (57) | 1.9 | 0.6-5.9 | .2 |
| All other | 56 | 22 (39) | — | — | — |
| Response to ECP‡ | |||||
| CR/PR | 37 | 9 (24) | 0.2 | 0.1-0.5 | < .001 |
| All others | 25 | 17 (65) | — | — | — |
| Platelets at ECP | |||||
| Fewer than 100 000/mm3§ | 24 | 16 (67) | 7.25 | 3.1-16.9 | < .001 |
| 100 000/mm3 or more | 38 | 10 (26) | — | — | — |
| Unknown | 1 | 2 (—) | — | — | — |
| LDH | |||||
| 1000 IU/L or less | 41 | 14 (35) | — | — | — |
| More than 1000 IU/L | 20 | 12 (60) | 3.1 | 1.4-6.9 | .005 |
| Unknown | 2 | — (—) | — | — | — |